google_counter
background_img

Prostate Cancer Treatment with Actinium-225 PSMA (program ID: 447956)

University Hospital RWTH Aachen

location_on Aachen, Germany
8.9/10 from 41 Votes
Specialized hospital
Felix Manuel Mottaghy

Head Physician
Prof. Dr. med.

Felix Manuel Mottaghy

Specialized in: nuclear medicine

Department of Nuclear Medicine

Program includes:

  • Initial presentation in the clinic
  • clinical history taking
  • general physical examination
  • laboratory tests:
    • complete blood count
    • biochemical analysis of blood
    • urinalysis
    • TSH-basal, fT3, fT4
    • PSA blood level
    • tests for urogenital infections
    • indicators of inflammation
    • indicators of blood coagulation
  • ultrasound scan of the urogenital system
  • renal scintigraphy
  • PSMA PET-CT
  • PSMA treatment with Actinium-225
  • full body scintigraphy after 24 hours
  • full body scintigraphy after 48 hours
  • symptomatic treatment
  • cost of essential medicines
  • nursing services
  • elaboration of further recommendations
  • stay in the hospital with full board 
  • accommodation in 2-bedded room 

How program is carried out

During the first visit, the doctor will carry out a general physical examination and go through the results of previous laboratory and instrumental tests. After that, you will undergo the necessary additional tests such as the assessment of liver and kidney function, scintigraphy of the skeleton and salivary glands, PSMA PET / CT. This will allow the doctor to assess how effective PSMA therapy with Actinium-225 will be and how well you will tolerate it. Also, the doctor will calculate your individual dosage of the radionuclide.

PSMA therapy with Actinium-225 is carried out via intravenous administration of a solution with the radioactive isotope Actinium-225. The solution is injected through a catheter. This is a short procedure, as the infusion usually takes no more than 20 minutes.

During the procedure, you will need to apply cooling bags to the salivary glands, as Actinium-225 partially accumulates in the salivary glands, affecting their function and causing dry mouth. You will also receive intravenous saline solutions to protect your kidneys.

After the infusion of Actinium-225, you will stay in a specially equipped (radiation-shielded) ward for 48 hours. The drug is quickly excreted by the kidneys, and after 48 hours you will no longer be dangerous to others. During these 48 hours, you can read, use a mobile phone, tablet or computer – all these devices will not be a source of radiation in the future.

Follow-up examinations include whole-body scintigraphy or computed tomography in 24 hours and 48 hours after the procedure. Based on the results of the examination, the doctor will determine whether one procedure is enough for you, or whether you will need to visit the hospital again. As a rule, 1-2 procedures are required for achieving a stable positive result. Procedures are carried out with an interval of 8 weeks.

Required documents

  • Medical records
  • PSA blood test
  • MRI/CT scan (not older than 3 months)
  • Bone scintigraphy (if available)
  • Biopsy results (if available)
Service
Price:
Type of program :
Expected duration of the program:

You may also book

Price:

About the department

The Department of Nuclear Medicine at the University Hospital RWTH Aachen offers all the modern options of diagnostics and treatment using radioisotopes. Of particular interest in the field of diagnostics are PET, PET-CT, SPECT and scintigraphy. The key attention is also given to the diagnostics and treatment of thyroid diseases (thyroid scintigraphy and radioiodine therapy). In addition, the department's competence covers the diagnostics and treatment of diseases of the joints, prostate cancer, liver tumors, other benign and malignant pathologies. The Chief Physician of the department is Prof. Dr. med. Felix Manuel Mottaghy.

Special attention should be paid to the advanced technical base and outstanding professionalism of doctors. All this allows the doctors to provide medical services of the highest standard, as well as to implement innovative treatment methods into clinical practice. At the center of all the efforts of the department's employees is the patient with his individual needs and wishes.

The service range of the department includes:

  • Diagnostics
    • Thyroid radioisotope diagnostics
    • Radioisotope diagnostics of the heart and lungs
    • Kidney radioisotope diagnostics
    • Radioisotope diagnostics of abdominal organs
    • Scintigraphy of various organs
    • SPECT
    • Molecular imaging using PET/PET-CT
      • 18F-FDG PET/PET-CT (for tumor staging, therapy effectiveness monitoring, diagnostics of dementia)
      • 18F-choline PET/PET-CT (for tumor staging, diagnostics of relapse)
      • 18 F-FDOPA PET/PET-CT (for tumor staging, diagnostics of relapse)
      • 18F-FET PET/PET-CT (for the diagnostics of relapse)
      • 18F-florbetapir PET/PET-CT (for the diagnostics of dementia)
      • 68Ga DOTATOC PET/PET-CT (for tumor staging)
      • 68Ga PSMA PET/PET-CT (for tumor staging, diagnostics of relapse)
  • Therapy
    • Radioiodine therapy for the treatment of benign thyroid diseases
    • Radioiodine therapy for the treatment of malignant thyroid diseases
    • Radiosynoviorthesis for the treatment of joint diseases
    • Selective internal radiation therapy
    • Peptide receptor radionuclide therapy
    • 177Lu PSMA therapy for prostate cancer
  • Other diagnostic and therapeutic options

Curriculum vitae

Education

  • 1990 - 1996 Study of Human Medicine at the RWTH Aachen University and at the University of Utah, Salt Lake City, USA.
  • 1995 - 1996 Practical year at the Luisenhospital Aachen (Surgery), at the University of Utah, Salt Lake City, USA (Internal Medicine) and at the University Hospital RWTH Aachen (Neurology).

Qualifications

  • 09.12.1996 State Examination in Medicine.
  • 09.12.1996 Admission to medical practice (preliminary).
  • 1997 1st and 2nd stage of the United States Medical Licensing Examination (USMLE).
  • 10.03.1998 Doctoral thesis defense at the RWTH Aachen University.
  • 01.09.1998 Admission to medical practice.
  • 23.01.2003 Board certification in Nuclear Medicine.
  • 23.11.2004 Habilitation.

Professional Career

  • 03.1997 - 02.1998 Intern, Department of Nuclear Medicine, University Hospital Duesseldorf.
  • 03.1998 - 08.1998 Intern, Department of Neurology, University Hospital RWTH Aachen.
  • 09.1998 - 05.2000 Assistant Physician, Department of Nuclear Medicine, Medical Facilities of the Heinrich Heine University at the Juelich Research Center GmbH, Juelich.
  • 06.2000 - 05.2001 Scholarship of the German Research Foundation, Department of Neurology, Harvard University, Boston, research focused on multimodal SPECT, MRI and TMS examination on neuroscience issues.
  • 06.2001 - 10.2002 Assistant Physician, Department of Nuclear Medicine, Medical Facilities of the Heinrich Heine University at the Juelich Research Center GmbH, Juelich.
  • 11.2002 - 01.2003 Acting Head of the Department of Nuclear Medicine, Medical Facilities of the Heinrich Heine University at the Juelich Research Center GmbH, Juelich.
  • 02.2003 - 11.2005 Senior Physician, Department of Nuclear Medicine, University Hospital Ulm.
  • 12.2005 - 12.2006 Senior Physician and Deputy Head of the Department of Nuclear Medicine, University Hospital Ulm.
  • 08.2006 Invitation to the position of Professor of Oncological Nuclear Medicine, Catholic University of Leuven.
  • Since 01.2007 Professor of Oncological Nuclear Medicine (Assistant Professor) and Deputy Head of the Department of Nuclear Medicine at the University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium.
  • Since 08.2008 Head and Coordinator of the Working Group on Preclinical Oncological Imaging, MoSAIC KU, Leuven.
  • 19.12.2008 Invitation to the position of W3 Professor in Nuclear Medicine, Faculty of Medicine, RWTH Aachen University.
  • Since 01.10.2009 Head of the Department of Nuclear Medicine at the University Hospital RWTH Aachen.

Membership in Professional Societies and Organizations

  • German Society of Nuclear Medicine (Head of the Committee of Advanced Training).
  • European Association of Nuclear Medicine (Active Member of the Cancer Committee).
  • European Organisation for the Research and Treatment of Cancer (EORTC) (Active Member of the Imaging Committee).
  • Main Reviewer of PET data in the H10 European Researchers (stage II Hodgkin's lymphoma).
  • Society of Nuclear Medicine.
  • Belgian Society of Nuclear Medicine.
  • European Neuroendocrine Tumor Society (ENETS).
  • German Society of Endocrinology.

Photo of the doctor: (c) Uniklinik RWTH Aachen 


About hospital

Accommodation in hospital

There are 26 metastatic prostate cancer treatment hospitals on Booking Health website

Show all clinics

Need Help?

Thank you!

We received your treatment application in the best Europe clinics. Our manager will contact you within the next 24 hours.